IDH2 and central nervous system cancer: IDH1 and IDH2 mutations have been co-targeted though molecules such as AG-881, which is currently being evaluated in the phase 3 INDIGO trial (NCT04164901) in patients with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation (93).